Statements (37)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral
|
| gptkbp:alsoKnownAs |
gptkb:Imatinib
|
| gptkbp:approvalYear |
2001
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XE01
|
| gptkbp:CASNumber |
152459-95-5
|
| gptkbp:category |
protease inhibitor
antineoplastic agent |
| gptkbp:chemicalFormula |
C29H31N7O
|
| gptkbp:developedBy |
gptkb:Novartis
|
| gptkbp:eliminationHalfLife |
18 hours
|
| gptkbp:excretion |
urine
feces |
| https://www.w3.org/2000/01/rdf-schema#label |
Glivec
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
gptkb:receptor_tyrosine_kinase
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
493.6 g/mol
|
| gptkbp:patentExpired |
2015 (US)
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:sideEffect |
nausea
edema fatigue rash muscle cramps |
| gptkbp:target |
gptkb:PDGFR
gptkb:c-KIT gptkb:BCR-ABL_protein |
| gptkbp:usedFor |
gptkb:chronic_myeloid_leukemia
leukemia gastrointestinal stromal tumors |
| gptkbp:bfsParent |
gptkb:CHEMBL958
gptkb:imatinib_(Gleevec) gptkb:Gleevec gptkb:112809-51-5 |
| gptkbp:bfsLayer |
6
|